Search clinical trials for: CD20 aggressive lymphoma

Total 11173 results

OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Completed

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
The University of Hong Kong

Completed

Optimizing HBV Management During Anti-CD20 Antibodies

Hepatitis B | Liver Dysfunction | Immune Suppression

Hong Kong
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Sjogren's Syndrome

United States
University Hospital, Rouen

Completed

Effect of Anti CD20 in Pemphigus Desease

Pemphigus

France
Beijing Friendship Hospital

Enrolling by invitation

Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV

CAEBV | PTLD | HLH

China
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Takeda

Terminated

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis (VELVET)

Rheumatoid Arthritis

United States, Argentina, Canada, Czech Republic, Germany, Hungary, Italy, Mexico, Poland, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
Universität des Saarlandes
Spectrum Pharmaceuticals, Inc; German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (OPTIMAL>60)

CD20+ Aggressive B-Cell Lymphoma

Germany
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma and Marginal Zone Lymphoma

China
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China
Probiomed S.A. de C.V.

Unknown

TREatment of degeNerative and Neoplastic Diseases With Rituximab (TREND)

Diffuse Large B Cell Lymphoma

Mexico
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

CD20 Positive B Cell Non-Hodgkin's Lymphoma

China
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
Zhejiang Teruisi Pharmaceutical Inc.

Recruiting

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

CD20-positive B-cell Non-Hodgkin Lymphoma

China
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

Completed

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

Posttransplant Lymphoproliferative Disorder

Germany
National Cancer Institute (NCI)

Completed

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Gilead Sciences

Completed

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Lymphoma, Diffuse | Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic

France, United Kingdom
Beijing Mabworks Biotech Co., Ltd.

Completed

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

CD20-positive B Cell Non-Hodgkin Lymphoma

China
Applied Molecular Evolution

Completed

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Heidelberg University

Recruiting

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody (FORTplus)

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a

Germany
Amsterdam UMC, location VUmc
Stichting Treatmeds

Recruiting

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS (Noisy Rebels)

Nervous System Diseases | Multiple Sclerosis | Demyelinating Autoimmune Diseases, CNS | Autoimmune Diseases of the Nervous System | Demyelinating Diseases | Multiple Sclerosis, Relapsing-Remitting

Netherlands
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
Chinese SLE Treatment And Research Group

Recruiting

Anti-CD20 Antibodies for Treatment of SLE-PAH

Systemic Lupus Erythematosus | Pulmonary Arterial Hypertension

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

CD20-positive B-cell Non-Hodgkin's Lymphoma

China
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Shanghai Public Health Clinical Center

Unknown

The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma

To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
Fate Therapeutics

Terminated

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia

United States
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Han weidong

Unknown

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)

Lymphomas
Alexey Danilov, MD
Gilead Sciences; Oregon Health and Science University

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Anemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditions

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; University of Rochester and other collaborators

Completed

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Non-Hodgkin's Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Mantle Cell Lymphoma | CD20 Positive

United States
The First Affiliated Hospital of Soochow University

Enrolling by invitation

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

China
The Lymphoma Academic Research Organisation

Completed

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma

Belgium, France
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

B-Cell Lymphoma

China
Region Örebro County

Recruiting

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults (RCT-RITS)

Schizophrenia Spectrum and Other Psychotic Disorders

Sweden
Mayo Clinic

Completed

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

COVID-19 | Convalescent Plasma | Immunosuppressed Host | Anti-CD20 Therapy

United States
Han weidong

Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T Cells

China
University Health Network, Toronto
Hoffmann-La Roche; Ozmosis Research Inc.

Completed

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin's

Canada
Weill Medical College of Cornell University

Completed

Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies

Lymphoma

United States
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Asan Medical Center

Withdrawn

R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL (ASPIRE)

Diffuse Large B-cell Lymphoma

Korea, Republic of

Search clinical trials for: CD20 aggressive lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations